



Published in final edited form as:

Int J Parasitol. 2019 February ; 49(2): 145–151. doi:10.1016/j.ijpara.2018.06.006.

Investigating disease severity in an animal model of concurrent babesiosis and Lyme disease

Purnima Bhanot^a and Nikhat Parveen^{a,*}

^aDepartment of Microbiology, Biochemistry and Molecular Genetics, Rutgers New Jersey Medical School, Newark, NJ, USA


Abstract

The incidence of babesiosis, Lyme disease and other tick-borne diseases has increased steadily in Europe and North America during the last five decades. *Babesia microti* is transmitted by species of *Ixodes*, the same ticks that transmit the Lyme disease-causing spirochete, *Borrelia burgdorferi*. *B. microti* can also be transmitted through transfusion of blood products and is the most common transfusion-transmitted infection in the U.S.A. *Ixodes* ticks are commonly infected with both *B. microti* and *B. burgdorferi*, and are competent vectors for transmitting them together into hosts. Few studies have examined the effects of coinfections on humans and those have had somewhat contradictory results. One study linked coinfection with *B. microti* to a greater number of symptoms of overall disease in patients, while another report indicated that *B. burgdorferi* infection either did not affect babesiosis symptoms or decreased its severity. Mouse models of infection that manifest pathological effects similar to those observed in human babesiosis and Lyme disease offer a unique opportunity to thoroughly investigate the effects of coinfection on the host. Lyme disease has been studied using the susceptible C3H mouse infection model, which can also be used to examine *B. microti* infection to understand pathological mechanisms of human diseases, both during a single infection and during coinfections. We observed that high *B. microti* parasitaemia leads to low haemoglobin levels in infected mice, reflecting the anemia observed in human babesiosis. Similar to humans, *B. microti* coinfection appears to enhance the severity of Lyme disease-like symptoms in mice. Coinfected mice have lower peak *B. microti* parasitaemia compared to mice infected with *B. microti* alone, which may reflect attenuation of babesiosis symptoms reported in some human coinfections. These findings suggest that *B. burgdorferi* coinfection attenuates parasite growth while *B. microti* presence exacerbates Lyme disease-like symptoms in mice.

Graphical Abstract

*Corresponding author. Parveeni@njms.rutgers.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Keywords

Babesia microti; Babesiosis; *Borrelia burgdorferi*; Coinfections; Tick-borne diseases

1. Introduction

Babesia microti and *Borrelia burgdorferi* cause two of the most prominent tick-borne diseases in the U.S.A., human babesiosis and Lyme disease, respectively. Transmission of these pathogens is primarily through species of *Ixodes* ticks. In addition to the shared tick vector, *B. microti* and *B. burgdorferi* have common animal reservoirs and overlap in their epidemiology and transmission cycles (Spielman et al., 1985; Oliver et al., 1993; Swanson et al., 2006). The white-footed mouse is the primary reservoir host for both pathogens and the white-tailed deer has contributed to expansion of the endemic regions for both diseases in the U.S.A. (Telford et al., 1996; Levin et al., 2002; Thomas et al., 2009; Ismail et al., 2010; Magnarelli et al., 2010; Rikihisa, 2010). *Babesia* species were identified as infectious organisms in 1893 and babesiosis was first detected in humans in the U.S.A. in 1969 (Western et al., 1970; Ouhelli and Schein, 1988). In 1991, one of 13 babesiosis cases in Connecticut, U.S.A. was transmitted through a blood transfusion (Anderson et al., 1991). Soon after *B. burgdorferi* identification as the causative agent of Lyme disease (Burgdorfer et al., 1982), it was shown to cause coinfections with *B. microti* in hamsters through *Ixodes dammini/scapularis* ticks (Piesman et al., 1987). Both pathogens were recovered concurrently from rodents, *Peromyscus leucopus* and *Microtus pennsylvanicus*, in northeastern U.S.A., indicating coinfection of reservoir hosts in the field (Anderson et al., 1986, 1987; Stafford et al., 1999; Magnarelli et al., 2013). *Babesia microti* is transmitted less efficiently by ticks relative to *B. burgdorferi* (Krause et al., 2006). However, acquisition of *B. microti* from mice by the tick vector improves when mice are coinfecting with a highly infectious strain of *B. burgdorferi* (Dunn et al., 2014). The prior presence of *B. burgdorferi* in a geographical region and its coinfection enhances the expansion in range and establishment of *B. microti* in that region (Dunn et al., 2014), especially when larvae and nymphs feed together on a reservoir host. The higher incidence of babesiosis in long-established *B. burgdorferi* endemic regions relative to those where infection of ticks is more recent is likely due to underreporting of babesiosis in the latter (Diuk-Wasser et al., 2014).

Thorough investigations of coinfection with *B. microti* and *B. burgdorferi* in humans have started only in the last decade. Patients were considered coinfecting based on serological diagnostic tests, although serological results cannot always distinguish between prior exposure and an ongoing infection. Nearly 10% of patients in southern New England (U.S.A.) reporting tick bites exhibited evidence of infections with Lyme spirochetes and *B. microti* as early as the 1990s. Several Lyme disease and babesiosis symptoms overlap and are non-specific. Patients with exposure to both pathogens as determined serologically, with or without testing and evidence of spirochetal DNA in their blood, showed significantly more intense flu-like symptoms such as fatigue, chills, nausea, fever and headache that persisted for longer periods than patients infected only with *B. burgdorferi* (Krause et al., 1996, 2002, 2003). The same studies reported that coinfecting patients showed either no difference or displayed less severe symptoms compared with patients infected with *B. microti* alone. There is a clear need for further studies on the effects of *B. microti*-*B. burgdorferi* coinfections to determine the pathogenic mechanisms that exacerbate or mitigate disease symptoms. Here, we review infection of hosts with *B. microti* and *B. burgdorferi* and the impact of infection on the host immune system and disease manifestations inflicted by each pathogen. Using a mouse model of coinfection, we will discuss insights that can be gained into the pathogenesis of coinfections by *B. microti*-*B. burgdorferi*.

2. Babesiosis; an emerging parasitic disease

Babesia species belong to intracellular apicomplexan protozoa that multiply in the red blood cells (RBCs). *Babesia* undergoes repeated cycles of infection and asexual replication within erythrocytes. Their intra-erythrocytic multiplication causes cell lysis and results in hemolytic anemia. *Babesia microti*, and to some extent *Babesia duncani*, causes infection in humans in the U.S.A. while *Babesia divergens* is responsible for most cases of human babesiosis in Europe. According to the Centers for Disease Control and Prevention (CDC) of the U. S.A., 97% of cases of babesiosis in the USA in 2011 were caused by *B. microti*. These were reported primarily in the northeastern United States (Massachusetts, Connecticut, New York, New Jersey and Rhode Island) and Great Lakes region of Wisconsin and Minnesota (Herwaldt et al., 2003; Joseph et al., 2011). Immunocompetent people often remain asymptomatic or experience mild flu-like symptoms that include fever and aching muscles while immunocompromised, elderly or splenectomized individuals experience severe, acute and sometimes fatal babesiosis (Genda et al., 2016). The disease is very likely under-reported since initial symptoms are non-specific and testing requires a high index of suspicion from the clinician. Typically, physicians recommend testing for *Babesia* only after observing hemolytic anemia.

Transmission of *B. microti* through transfusion of blood products was recognized in 1994 (Gerber et al., 1994). Since babesiosis is the most common infection transmitted through blood transfusion in the U.S.A, the United States Food and Drug Administration (FDA) recently recommended screening blood and/or blood donors for *Babesia* infection (Lobo et al., 2013; <https://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM598243.pdf>). Individuals with fully competent immune systems can establish *Babesia* carriage states for prolonged durations without exhibiting infection-associated clinical manifestations and often donate blood. Since

these parasites survive during cold storage of donated blood, transfusion of tainted blood products can result in babesiosis in immunocompromised or splenectomized patients (Hunfeld et al., 2008; Herman et al., 2010; Chiang and Haller, 2011; Herwaldt et al., 2011; Sinski et al., 2011; van Vugt et al., 2011; Cushing and Shaz, 2012; Holler et al., 2013; ; Poisnel et al., 2013; Cursino-Santos et al., 2014; Fang and McCullough, 2016). Rare examples of transplacental transmission of *Babesia* have also been reported. In the cases of congenital babesiosis through mothers infected with either *Babesia* alone or coinfecting with Lyme spirochetes, infants suffer from jaundice, anemia, thrombocytopenia and neutropenia (Joseph et al., 2012; Luckett et al., 2014; Wormser et al., 2015; Saetre et al., 2018). A recent report showed a significant decrease in transfusion-transmitted babesiosis when donated blood was prescreened for *B. microti* DNA presence by quantitative PCR (qPCR) and for *anti-Babesia* antibodies by Arrayed Fluorescence Immunoassay (Moritz et al., 2016). Although not yet FDA approved for widespread application or commercially available, this type of screening, if employed universally in regions endemic for tick-borne diseases, can eventually eliminate the hazard of transfusion-transmitted babesiosis.

Age is a major risk factor for babesiosis in humans. Manifestations in elderly patients include low and unstable blood pressure, chills, pain, severe hemolytic anemia, disseminated intravascular coagulation and vital organ failure, and can even result in mortality (Krause et al., 2003; Joseph et al., 2011; Martinez-Balzano et al., 2015). It is likely that age-related weakening of the immune system prevents clearance of this parasite in the elderly. The spleen plays a critical role in the resolution of human babesiosis since asplenic/splenectomized people have a heightened risk of the disease (Krause et al., 2008; Raffalli and Wormser, 2016).

3. Lyme disease

Lyme disease is the most predominant tick-borne infectious disease. The CDC estimates that ~300,000 individuals are infected by *B. burgdorferi* every year in the U.S.A. (Kuehn, 2013) but only 10% of them are reported (Moore et al., 2016). Lyme disease starts with an early localized stage manifested as erythema migrans in up to 80% of infected individuals, followed by dissemination of spirochetes to different tissues, often manifested as multiple skin lesions with neuronal, joint and heart involvement. Late stages of infection display chronic arthritis, acrodermatitis and neuroborreliosis (Steere, 2001).

Similar to other pathogenic infections, Lyme disease pathogenesis is multifactorial. Both bacterial and host factors affect the severity of disease symptoms. The major outer surface protein A (OspA) and OspB of *B. burgdorferi* facilitate colonisation of the midgut in unfed ticks (Pal et al., 2000; Fikrig et al., 2004; Pal et al., 2004; Neelakanta et al., 2007). Down-regulation of OspA post-blood meal is concurrent with induction of OspC, a lipoprotein critical for initiation of mammalian infection (Grimm et al., 2004; Tilly et al., 2006). Interestingly, OspC is dispensable for later stages of mammalian infection, i.e., once the adaptive immune response is established in the infected mammal. After initial infection, several *B. burgdorferi* proteins interact with extracellular matrix (ECM) components to enable colonisation of a variety of mammalian tissues. Interaction of *B. burgdorferi* with endothelial cells (Leong et al., 1998; Ebady et al., 2016) is followed by dissemination to

various tissues, where colonisation occurs through recognition of fibronectin, glycosaminoglycan (GAG) and proteoglycan, decorin present on the host cell surface in ECM components, and is facilitated by spirochete proteins including BB0347, BBK32, Bgp and DbpA and DbpB in mice (Parveen and Leong, 2000; Parveen et al., 2006; Seshu et al., 2006; Weening et al., 2008; Saidac et al., 2009; Benoit et al., 2011; Hyde et al., 2011; Lin et al., 2012, 2015; Schlachter et al., 2018). Only P66 and BBB07 of *B. burgdorferi* have been shown to recognize integrins present in the host cell cytoplasmic membrane (Behera et al., 2008; Ristow et al., 2015). Some of these *B. burgdorferi* proteins that participate in cell adherence also contribute to the long-term survival of spirochetes in tissues. Knockout mutants of these adhesins often result in attenuated Lyme disease in mice (Parveen et al., 2006; Parveen and Leong, 2006; Shi et al., 2006; Blevins et al., 2008; Weening et al., 2008; Hyde et al., 2011; Schlachter et al., 2018).

4. Host immune response against *B. microti* and *B. burgdorferi* infections

The immune response during intracellular multiplication of *B. microti* was defined by a case study that was followed by a proposed model depicting the specific cell involvement (Shaio and Lin, 1998; Homer et al., 2000). In these reports, innate immune responses facilitated by both macrophage and natural killer (NK) cells were implicated in the control of this parasite in humans in the acute phase, and was likely facilitated by production of IL-2, IL-12, TNF- α and IFN- γ by these cells. The mechanisms involved in inhibition of the intra-erythrocytic cycle of *B. microti* are still not well understood. In some mouse models, macrophages and NK cells, together with IL-12 and IFN- γ , were found to play important roles in the resolution of *B. microti* parasitaemia and protection from future infections (Igarashi et al., 1999; Chen et al., 2000; Aguilar-Delfin et al., 2003). In addition to the host genotype, the strain of *B. microti* affects the anti-parasitic immune response. In mice, IFN- γ is required but not essential for the control of infection by some but not all *B. microti* strains. Several previous studies suggested that depending on the protozoan strain used for infection, IFN- γ could be required but not essential for control of *B. microti* parasitaemia in mice (Matsubara et al., 1993; Igarashi et al., 1999; Clawson et al., 2002; Skariah et al., 2017).

Borrelia burgdorferi induces protective, albeit proinflammatory, immune responses in the host, which contribute to Lyme arthritis. The innate response, by modulating Toll like receptor (TLR) signaling, enables host defense against *B. burgdorferi* but also increases inflammation and disease severity. TLR2 signaling pathways activated by *B. burgdorferi* lipoproteins play pivotal roles in the control of spirochetes in joints, the induction of pro-inflammatory cytokines by host macrophages, and in increasing Lyme arthritis (Wooten et al., 2002; Wang et al., 2008; Dennis et al., 2009; Salazar et al., 2009; Iliopoulou and Huber, 2010). Interestingly, a TLR1 polymorphism causes an increase in Th1 immune responses and poses a risk of antibiotic-refractory Lyme arthritis in humans (Strle et al., 2012). TLR1/TLR2 heterodimers are also important for stimulating immune responses against *B. burgdorferi* such that both TLR2 and MyD88 knockout mutants showed increased tissue colonisation and severe arthritis (Alexopoulou et al., 2002; Yoder et al., 2003; Marre et al., 2010). Activation of TLR8 by *B. burgdorferi*-derived RNA in monocytes also induces Type I interferon and IFN-responsive host genes and contributes to the severity of Lyme arthritis (Miller et al., 2010). Increased production of IFN- γ , resulting from induction of a Th1

response, as reported in *B. burgdorferi*-infected patients relative to uninfected controls, was found to contribute to increased Lyme disease pathogenesis. This immune response also correlates with potential autoimmune reactions depending on the age or genotype of the host. Genetic constitution (HLA-DR haplotypes) and associated autoimmune responses may underline susceptibility of humans to post-treatment Lyme syndrome. Attempts to model antibiotic-refractory Lyme arthritis in mouse models have had mixed results (Iliopoulou et al., 2009; Steere et al., 2011). Therefore, factors contributing to chronic/treatment refractory inflammatory Lyme disease remain poorly understood.

5. Impact of *B. microti*-*B. burgdorferi* coinfections on disease manifestation

As early as 1985, serological testing in endemic regions demonstrated coinfections with *B. burgdorferi* in 54% of patients with babesiosis, and with *B. microti* in 64% of Lyme disease patients (Benach et al., 1985). Since then, high levels of coinfections with *Borrelia* and *Babesia* spp. continue to be reported in Australia (Mayne, 2011, 2015), northeastern and midwestern U.S.A. with a reported rate of 32–40% in patients examined in New England (Anderson et al., 1991; Krause et al., 1991; Mitchell et al., 1996; Belongia, 2002), which is similar to a coinfection rate of 38.5% we observed in New Jersey (Primus et al., 2018). Some studies have found *B. burgdorferi*-*B. microti* to be the most common coinfection representing as high as 81% of tick transmitted coinfections in New England regions of the U.S.A. (Swanson et al., 2006). Long-term clinical outcomes of coinfections are likely influenced by the genetic compositions of pathogenic strains of *B. microti* and *B. burgdorferi*, differential immunological responses in patients, and the potential contribution of additional coinfecting tick-borne pathogens.

Symptoms such as chills, fever, fatigue, headache and general malaise occur in both Lyme disease and babesiosis (Pruthi et al., 1995). Coinfections can have serious consequences and have complex clinical manifestations including those associated with cardiac involvement. A patient who showed persistent fever, chills, myalgias, erythematous skin lesions and 3% *B. microti* parasitaemia displayed pericarditis prior to death (Marcus et al., 1985). An autopsy revealed the presence of *B. burgdorferi* spirochetes in the myocardium, suggesting that the severity of Lyme carditis was responsible for this death (Marcus et al., 1985). In contrast to cardiac manifestations, the number and persistence of musculoskeletal or neurological symptoms in patients with simultaneous infections with both pathogens were not reported to be higher than in patients infected only with *B. burgdorferi* (Krause et al., 1996), but there is one report of severe transverse myelitis in a coinfecting patient (Oleson et al., 2003). While coinfections with *B. microti* worsen some acute symptoms of Lyme disease, long-term (on average 6 months post-exposure) outcomes of Lyme disease were the same in coinfecting and only *B. burgdorferi*-infected patients (Wang et al., 2000). One confounding feature of human coinfections is the challenge of distinguishing concurrent infections from previous exposure to each pathogen.

6. Mouse models of infections and *B. microti*-*B. burgdorferi* coinfections

Mice are natural hosts for both *B. microti* and *B. burgdorferi*. Selected laboratory mouse strains infected with *B. microti* and *B. burgdorferi* exhibit pronounced disease manifestations, enabling the development of mouse models of Lyme disease and human babesiosis. The experimental accessibility of mouse models of coinfection can provide valuable information on pathogenic mechanisms and host immune responses during concurrent or sequential infections with the two pathogens. The ability to control infectious doses, timing of infection, together with host and pathogen genotypes, provide a unique opportunity to obtain insights relevant to human diseases.

Host gender is an important variable in the outcome of infectious diseases. One study found the incidence of babesiosis to be significantly higher in men than women (Menis et al., 2015). The data in mice is somewhat conflicting. Infection of several strains of moderately susceptible mice with the highly infectious *B. microti* strain, WA1, caused higher mortality in female than male mice (Aguilar-Delfin et al., 2001). However, infection with *B. microti* Munich strain lead to higher peak parasitaemia and greater anemia in males of several strains compared with respective strains female mice (Sasaki et al., 2013). These varying results highlight the need to consider the effects of both the host and *B. microti* genotypes on the course of infection in mice of both sexes.

Age is a well-known risk factor in human babesiosis. In addition, DBA/2 mice displayed an age-related increase in susceptibility to *B. microti* strain RM/NS. Early peak parasitaemia were higher in older DBA/2 mice compared with younger ones (Vannier et al., 2004). Older mice were also compromised in clearing the parasite and, after resolution of the initial peak, displayed persistent low-level parasitaemia for a longer time as compared with younger mice (Vannier et al., 2004).

There are only two published reports on *B. microti*-*B. burgdorferi* coinfections in mice (Moro et al., 2002; Coleman et al., 2005) and these provided inconsistent results. One study examined coinfection and infections with each pathogen individually, in BALB/c and C3H/HeN mice (Coleman et al., 2005). The impact of coinfection, relative to either *B. microti*- or *B. burgdorferi*-associated symptoms, was not found to be statistically significant. Thus, coinfection did not exacerbate *B. microti* parasitaemia, associated splenomegaly, decrease in hematocrit, haemoglobin levels and platelet count since all parameters were similar to *B. microti*-infected, normal, aged and splenectomized mice (Coleman et al., 2005). A puzzling result in this study is the lower peak parasitaemia in old versus young C3H/HeN mice infected only with *B. microti* (Coleman et al., 2005) since it is at odds with an age-related increase in susceptibility reported in humans after *B. microti* infection and in other strains of mice (Vannier et al., 2004). Thus, the results of Coleman and colleagues suggested that the course of *B. microti* infection is unaffected by concomitant infection with *B. burgdorferi*. Interestingly, coinfecting mice displayed similar *B. burgdorferi* burdens in tissues and ankle swelling compared with mice infected with *B. burgdorferi* alone in their study.

The second study (Moro et al., 2002) found increased Lyme arthritis in coinfecting BALB/c mice compared with mice infected exclusively with *B. burgdorferi*. Increased ankle swelling was attributed to simultaneous reduction in IL-10, produced by splenocytes and localized lymph nodes at approximately 4 weeks p.i., in coinfecting mice compared with *B. burgdorferi*-infected BALB/c mice (Moro et al., 2002). The inconsistent outcomes of coinfections reported in these two studies (Moro et al., 2002; Coleman et al., 2005) highlight the need for further development of a murine model of *B. microti*-*B. burgdorferi* coinfection.

To fill the gap in understanding of coinfections in mice, we recently began studies in C3H mice. To evaluate the effect of coinfections by these pathogens, young (4 weeks old), female C3H/HeJ mice were infected through i.p. injection of *B. microti* Gray strain-infected RBCs (1×10^4 per mouse) and s.c. injection of the infectious *B. burgdorferi* N40 strain (1×10^3 per mouse), either singly or together. We observed that *B. burgdorferi* colonisation diminished in female mice at 3 weeks p.i., while coinfecting mice continued to show significantly higher colonisation of joints and brain (unpublished data). As a consequence, coinfecting mice demonstrated increased inflammatory Lyme arthritis compared with mice infected only with *B. burgdorferi*. Our results are in agreement with a previous report on Lyme disease patients with concurrent babesiosis that showed exacerbation and persistence of acute Lyme disease symptoms compared with patients inflicted with Lyme disease alone (Krause et al., 1996, 2002). Interestingly, unlike the case in humans, carditis in coinfecting mice was indistinguishable from mice infected with *B. burgdorferi* alone. These differences point to the need for additional studies using mouse models of coinfection that replicate different disease manifestations observed in humans. Despite these differences, understanding of human illness during simultaneous infection with *B. burgdorferi* and *B. microti* can be facilitated using the mouse models of coinfection that replicate different disease manifestations observed in humans.

Coinfection with *B. burgdorferi* did not affect the rate of growth of *B. microti* but the peak *B. microti* parasitaemia in coinfecting mice was significantly lower than in mice infected only with *B. microti*. Giemsa-stained blood smears at peak parasitaemia during *B. microti* infection display pleomorphic, intracellular forms of *B. microti* and a significant reduction in erythrocytes resulting in anemia (Fig. 1). Following this peak parasitaemia, there was a marked reduction in haemoglobin levels in both *B. microti*-infected and coinfecting mice, with mice infected with *B. microti* only displaying slightly lower haemoglobin levels than coinfecting mice (Fig. 1B and C). Resolution of *B. microti* parasitaemia was associated with rapid restoration of haemoglobin levels in both sets of mice, suggesting that long-term effects of the *B. microti* infection cycle are minimal in this mouse model. Our results are consistent with reports of Lyme disease patients coinfecting with *B. microti* displaying less severe symptoms of babesiosis than patients infected with *B. microti* alone (Krause et al., 2002; Diuk-Wasser et al., 2016).

The spleen is proposed to be the most important lymphoid organ in antibody production during protozoan infections (Lundqvist et al., 2010; Bermejo et al., 2011). The major impact of *B. microti* infection in C3H mice, in the presence or absence of *B. burgdorferi*, was splenomegaly with the spleen weight of *B. microti*-infected mice 4-5 times that of *B. burgdorferi*-infected mouse spleens, underlining the central role played by this organ in

clearance of infected RBCs. The architecture of the spleen is significantly altered by *B. microti* infection (Fig. 2). The marginal zone merges with red and white pulp zones and the clear demarcation of these zones observed in uninfected or *B. burgdorferi*-infected mice disappears. Unlike in other infectious diseases, the spleen has been proposed to be the most important lymphoid organ playing a role in antibody production during protozoan infections (Lundqvist et al., 2010; Bermejo et al., 2011). We observed a significant decrease in both splenic T and B cells in *B. microti*-infected and coinfecting mice relative to those in only *B. burgdorferi*-infected mice. A more dramatic effect was observed on the B cell population. These results are consistent with observations in other protozoan diseases including Chagas disease and malaria, where specific B-cell responses against parasites are delayed or abrogated due to B cell apoptosis and their depletion in the spleen (Radwanska et al., 2008; Bockstal et al., 2011; Obishakin et al., 2014; Liu et al., 2015). Interestingly, specific antibody responses against both of these tick-borne pathogens in our study were significantly lower in coinfecting mice compared with mice infected with either pathogen individually. The decreased antibody response in coinfecting mice could explain the increased burden of Lyme spirochetes in tissues of coinfecting mice. In addition, these results potentially imply a relatively minor role for antibodies in clearance of the parasite since *B. microti* parasitaemia was lower in coinfecting mice compared with mice infected with *B. microti* alone. Coinfecting mice also demonstrated a significant increase in splenic macrophage numbers (unpublished data). Overall, our results suggest that a thorough investigation of the immune response is warranted to fully understand the pathogenesis of each disease during coinfection.

To summarize, various studies suggest that *B. microti* enhances *B. burgdorferi* colonisation and Lyme disease manifestations while *B. burgdorferi* attenuates *B. microti* parasitaemia. In addition, innate immune responses stimulated by *B. burgdorferi*, probably due to its large number of lipoproteins, could diminish *B. microti* growth and enhance parasitic resolution. The diminished cellular and humoral immune responses could be responsible for a higher *B. burgdorferi* burden in organs and tissues but these did not seem to affect resolution of babesiosis in mice. The spleen appears to be critical for elimination of *B. microti* infection in both humans and mice. Overall, all of these studies indicate that mouse coinfection models will improve the understanding of human infections with *B. burgdorferi* and *B. microti* separately or simultaneously.

7. Ethics Statement

Data generated from animal studies conducted by the laboratory of the corresponding author is included in this article. Designated members of Rutgers New Jersey Medical School, Newark Institutional Animal Care and Use Committee (IACUC), U.S.A., reviewed and approved the protocol number D-14011-A1 under which experiments were conducted following guidelines of the Animal Welfare Act, The Institute of Laboratory Animal Resources Guide for the Care and Use of Laboratory Animals, and Public Health Service Policy, U.S.A.

Acknowledgements

We thank Luke Fritzky and Joel Pierre for preparation of organ samples, their sectioning followed by H & E staining for the histopathological examination, and Dr. Vitomir Djokic for helping in preparation of the graphical abstract for this article. Data presented here were based on the studies supported by a New Jersey Health Foundation (U.S.A.) grant (to NP).

References

- Aguilar-Delfin I, Homer MJ, Wettstein PJ, Persing DH, 2001 Innate resistance to *Babesia* infection is influenced by genetic background and gender. *Infect Immun* 69, 7955–7958. [PubMed: 11705985]
- Aguilar-Delfin I, Wettstein PJ, Persing DH, 2003 Resistance to acute babesiosis is associated with interleukin-12- and gamma interferon-mediated responses and requires macrophages and natural killer cells. *Infect Immun* 71, 2002–2008. [PubMed: 12654819]
- Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT, Medzhitov R, Fikrig E, Flavell RA, 2002 Hyporesponsiveness to vaccination with *Borrelia burgdorferi* OspA in humans and in TLR1- and TLR2-deficient mice. *Nat Med* 8, 878–884. [PubMed: 12091878]
- Anderson JF, Johnson RC, Magnarelli LA, 1987 Seasonal prevalence of *Borrelia burgdorferi* in natural populations of white-footed mice, *Peromyscus leucopus*. *J Clin Microbiol* 25, 1564–1566. [PubMed: 3624451]
- Anderson JF, Johnson RC, Magnarelli LA, Hyde FW, Myers JE, 1986 *Peromyscus leucopus* and *Microtus pennsylvanicus* simultaneously infected with *Borrelia burgdorferi* and *Babesia microti*. *J Clin Microbiol* 23, 135–137. [PubMed: 3517038]
- Anderson JF, Mintz ED, Gadbaw JJ, Magnarelli LA, 1991 *Babesia microti*, human babesiosis, and *Borrelia burgdorferi* in Connecticut. *J Clin Microbiol* 29, 2779–2783. [PubMed: 1757548]
- Behera AK, Durand E, Cugini C, Antonara S, Bourassa L, Hildebrand E, Hu LT, Coburn J, 2008 *Borrelia burgdorferi* BBB07 interaction with integrin alpha3beta1 stimulates production of pro-inflammatory mediators in primary human chondrocytes. *Cell Microbiol* 10, 320–331. [PubMed: 17822440]
- Belongia EA, 2002 Epidemiology and impact of coinfections acquired from *Ixodes* ticks. *Vector-borne Zoonot Dis* 2, 265–273.
- Benach JL, Coleman JL, Habicht GS, MacDonald A, Grunwaldt E, Giron JA, 1985 Serological evidence for simultaneous occurrences of Lyme disease and babesiosis. *J Infect Dis* 152, 473–477. [PubMed: 4031555]
- Benoit VM, Fischer JR, Lin YP, Parveen N, Leong JM, 2011 Allelic variation of the Lyme disease spirochete adhesin DbpA influences spirochetal binding to decorin, dermatan sulfate, and mammalian cells. *Infect Immun* 79, 3501–3509. [PubMed: 21708995]
- Bermejo DA, Amezcua Vesely MC, Khan M, Acosta Rodriguez EV, Montes CL, Merino MC, Toellner KM, Mohr E, Taylor D, Cunningham AF, Gruppi A, 2011 *Trypanosoma cruzi* infection induces a massive extrafollicular and follicular splenic B-cell response which is a high source of non-parasite-specific antibodies. *Immunology* 132, 123–133. [PubMed: 20875075]
- Blevins JS, Hagman KE, Norgard MV, 2008 Assessment of decorin-binding protein A to the infectivity of *Borrelia burgdorferi* in the murine models of needle and tick infection. *BMC Microbiol* 8, 82–94. [PubMed: 18507835]
- Bockstal V, Guirnalda P, Caljon G, Goenka R, Telfer JC, Frenkel D, Radwanska M, Magez S, Black SJ, 2011 *T. brucei* infection reduces B lymphopoiesis in bone marrow and truncates compensatory splenic lymphopoiesis through transitional B-cell apoptosis. *PLoS Pathog* 7, e1002089. [PubMed: 21738467]
- Burgdorfer W, Barbour AG, Hayes SF, Benach JL, Grunwaldt E, Davis JP, 1982 Lyme disease-a tick-borne spirochetosis? *Science* 216, 1317–1319. [PubMed: 7043737]
- Chen D, Copeman DB, Burnell J, Hutchinson GW, 2000 Helper T cell and antibody responses to infection of CBA mice with *Babesia microti*. *Parasite Immunol* 22, 81–88. [PubMed: 10652120]
- Chiang E, Haller N, 2011 Babesiosis: an emerging infectious disease that can affect those who travel to the northeastern United States. *Travel Med Infect Dis* 9, 238–242. [PubMed: 21862413]

- Clawson ML, Paciorkowski N, Rajan TV, La Vake C, Pope C, La Vake M, Wikel SK, Krause PJ, Radolf JD, 2002 Cellular immunity, but not gamma interferon, is essential for resolution of *Babesia microti* infection in BALB/c mice. *Infect Immun* 70, 5304–5306. [PubMed: 12183588]
- Coleman JL, LeVine D, Thill C, Kuhlown C, Benach JL, 2005 *Babesia microti* and *Borrelia burgdorferi* follow independent courses of infection in mice. *J Infect Dis* 192, 1634–1641. [PubMed: 16206079]
- Cursino-Santos JR, Alhassan A, Singh M, Lobo CA, 2014 *Babesia*: impact of cold storage on the survival and the viability of parasites in blood bags. *Transfusion* 54, 585–591. [PubMed: 23888882]
- Cushing M, Shaz B, 2012 Transfusion-transmitted babesiosis: achieving successful mitigation while balancing cost and donor loss. *Transfusion* 52, 1404–1407. [PubMed: 22780893]
- Dennis VA, Dixit S, O'Brien SM, Alvarez X, Pahar B, Philipp MT, 2009 Live *Borrelia burgdorferi* spirochetes elicit inflammatory mediators from human monocytes via the Toll-like receptor signaling pathway. *Infect Immun* 77, 1238–1245. [PubMed: 19139200]
- Diuk-Wasser MA, Liu Y, Steeves TK, Folsom-O'Keefe C, Dardick KR, Lepore T, Bent SJ, Usmani-Brown S, Telford SR, 3rd, Fish D, Krause PJ, 2014 Monitoring human babesiosis emergence through vector surveillance New England, USA. *Emerg Infect Dis* 20, 225–231. [PubMed: 24447577]
- Diuk-Wasser MA, Vannier E, Krause PJ, 2016 Coinfection by *Ixodes* Tick-Borne Pathogens: Ecological, Epidemiological, and Clinical Consequences. *Trends Parasitol* 32, 30–42. [PubMed: 26613664]
- Dunn JM, Krause PJ, Davis S, Vannier EG, Fitzpatrick MC, Rollend L, Belperron AA, States SL, Stacey A, Bockenstedt LK, Fish D, Diuk-Wasser MA, 2014 *Borrelia burgdorferi* promotes the establishment of *Babesia microti* in the northeastern United States. *PLoS One* 9, e115494. [PubMed: 25545393]
- Ebady R, Niddam AF, Boczula AE, Kim YR, Gupta N, Tang TT, Odisho T, Zhi H, Simmons CA, Skare JT, Moriarty TJ, 2016 Biomechanics of *Borrelia burgdorferi* Vascular Interactions. *Cell Rep* 16, 2593–2604. [PubMed: 27568563]
- Fang DC, McCullough J, 2016 Transfusion-Transmitted *Babesia microti*. *Transfus Med Rev* 30, 132–138. [PubMed: 27260107]
- Fikrig E, Pal U, Chen M, Anderson JF, Flavell RA, 2004 OspB antibody prevents *Borrelia burgdorferi* colonisation of *Ixodes scapularis*. *Infect Immun* 72, 1755–1759. [PubMed: 14977984]
- Genda J, Negron EA, Lotfipour M, Balabhadra S, Desai DS, Craft DW, Katzman M, 2016 Severe *Babesia microti* Infection in an Immunocompetent Host in Pennsylvania. *J Investig Med High Impact Case Rep* 4, 2324709616663774.
- Gerber MA, Shapiro ED, Krause PJ, Cable RG, Badon SJ, Ryan RW, 1994 The risk of acquiring Lyme disease or babesiosis from a blood transfusion. *J Infect Dis* 170, 231–234. [PubMed: 8014507]
- Grimm D, Tilly K, Byram R, Stewart PE, Krum JG, Bueschel DM, Schwan TG, Policastro PF, Elias AF, Rosa PA, 2004 Outer-surface protein C of the Lyme disease spirochete: a protein induced in ticks for infection of mammals. *Proc Natl Acad Sci U S A* 101, 3142–3147. [PubMed: 14970347]
- Herman JH, Ayache S, Olkowska D, 2010 Autoimmunity in transfusion babesiosis: a spectrum of clinical presentations. *J Clin Apher* 25, 358–361. [PubMed: 20824620]
- Herwaldt BL, Linden JV, Bosserman E, Young C, Olkowska D, Wilson M, 2011 Transfusion-associated babesiosis in the United States: a description of cases. *Ann Intern Med* 155, 509–519. [PubMed: 21893613]
- Herwaldt BL, McGovern PC, Gerwel MP, Easton RM, MacGregor RR, 2003 Endemic babesiosis in another eastern state: New Jersey. *Emerg Infect Dis* 9, 184–188. [PubMed: 12603988]
- Holler JG, Roser D, Nielsen HV, Eickhardt S, Chen M, Lester A, Bang D, Frandsen C, David KP, 2013 A case of human babesiosis in Denmark. *Travel Med Infect Dis* 11, 324–328. [PubMed: 23849287]
- Homer MJ, Aguilar-Delfin I, Telford SR, 3rd, Krause PJ, Persing DH, 2000 Babesiosis. *Clin Microbiol Rev* 13, 451–469. [PubMed: 10885987]
- Hunfeldt KP, Hildebrandt A, Gray JS, 2008 Babesiosis: recent insights into an ancient disease. *Int J Parasitol* 38, 1219–1237. [PubMed: 18440005]

- Hyde JA, Weening EH, Chang M, Trzeciakowski JP, Hook M, Cirillo JD, Skare JT, 2011 Bioluminescent imaging of *Borrelia burgdorferi* in vivo demonstrates that the fibronectin-binding protein BBK32 is required for optimal infectivity. *Mol Microbiol* 82, 99–113. [PubMed: 21854463]
- Igarashi I, Suzuki R, Waki S, Tagawa Y, Seng S, Tum S, Omata Y, Saito A, Nagasawa H, Iwakura Y, Suzuki N, Mikami T, Toyoda Y, 1999 Roles of CD4(+) T cells and gamma interferon in protective immunity against *Babesia microti* infection in mice. *Infect Immun* 67, 4143–4148. [PubMed: 10417185]
- Iliopoulou BP, Guerau-de-Arellano M, Huber BT, 2009 HLA-DR alleles determine responsiveness to *Borrelia burgdorferi* antigens in a mouse model of self-perpetuating arthritis. *Arthritis Rheum* 60, 3831–3840. [PubMed: 19950279]
- Iliopoulou BP, Huber BT, 2010 Infectious arthritis and immune dysregulation: lessons from Lyme disease. *Curr Opin Rheumatol* 22, 451–455. [PubMed: 20375899]
- Ismail N, Bloch KC, McBride JW, 2010 Human ehrlichiosis and anaplasmosis. *Clin Lab Med* 30, 261–292. [PubMed: 20513551]
- Joseph JT, Purtill K, Wong SJ, Munoz J, Teal A, Madison-Antenucci S, Horowitz HW, Agüero-Rosenfeld ME, Moore JM, Abramowsky C, Wormser GP, 2012 Vertical transmission of *Babesia microti*, United States. *Emerg Infect Dis* 18, 1318–1321. [PubMed: 22840424]
- Joseph JT, Roy SS, Shams N, Visintainer P, Nadelman RB, Hosur S, Nelson J, Wormser GP, 2011 Babesiosis in lower hudson valley, new york, USA. *Emerg Infect Dis* 17, 843–847. [PubMed: 21529393]
- Krause PJ, Foley DT, Burke GS, Christianson D, Closter L, Spielman A, Tick-Borne Disease Study G, 2006 Reinfection and relapse in early Lyme disease. *Am J Trop Med Hyg* 75, 1090–1094. [PubMed: 17172372]
- Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR, 3rd, Christianson D, Dardick K, Coleman M, Giroto JE, Spielman A, 2008 Persistent and relapsing babesiosis in immunocompromised patients. *Clin Infect Dis* 46, 370–376. [PubMed: 18181735]
- Krause PJ, McKay K, Gadbaw J, Christianson D, Closter L, Lepore T, Telford SR, 3rd, Sikand V, Ryan R, Persing D, Radolf JD, Spielman A, 2003 Increasing health burden of human babesiosis in endemic sites. *American J Trop Med Hyg* 68, 431–436.
- Krause PJ, McKay K, Thompson CA, Sikand VK, Lentz R, Lepore T, Closter L, Christianson D, Telford SR, Persing D, Radolf JD, Spielman A, Deer-Associated Infection Study G, 2002 Disease-specific diagnosis of coinfecting tickborne zoonoses: babesiosis, human granulocytic ehrlichiosis, and Lyme disease. *Clin Infect Dis* 34, 1184–1191. [PubMed: 11941544]
- Krause PJ, Telford SR, 3rd, Ryan R, Hurta AB, Kwasnik I, Luger S, Niederman J, Gerber M, Spielman A, 1991 Geographical and temporal distribution of babesial infection in Connecticut. *J Clin Microbiol* 29, 1–4. [PubMed: 1993742]
- Krause PJ, Telford SR, 3rd, Spielman A, Sikand V, Ryan R, Christianson D, Burke G, Brassard P, Pollack R, Peck J, Persing DH, 1996 Concurrent Lyme disease and babesiosis. Evidence for increased severity and duration of illness. *JAMA* 275, 1657–1660. [PubMed: 8637139]
- Kuehn BM, 2013 CDC estimates 300,000 US cases of Lyme disease annually. *JAMA* 310, 1110. [PubMed: 24045727]
- Leong JM, Wang H, Magoun L, Field JA, Morrissey PE, Robbins D, Tatro JB, Coburn J, Parveen N, 1998 Different classes of proteoglycans contribute to the attachment of *Borrelia burgdorferi* to cultured endothelial and brain cells. *Infect Immun* 66, 994–999. [PubMed: 9488387]
- Levin ML, Nicholson WL, Massung RF, Sumner JW, Fish D, 2002 Comparison of the reservoir competence of medium-sized mammals and *Peromyscus leucopus* for *Anaplasma phagocytophilum* in Connecticut. *Vector-borne Zoonot Dis* 2, 125–136.
- Lin T, Gao L, Zhang C, Odeh E, Jacobs MB, Coutte L, Chaconas G, Philipp MT, Norris SJ, 2012 Analysis of an ordered, comprehensive STM mutant library in infectious *Borrelia burgdorferi*: insights into the genes required for mouse infectivity. *PLoS one* 7, e47532. [PubMed: 23133514]

- Lin YP, Chen Q, Ritchie JA, Dufour NP, Fischer JR, Coburn J, Leong JM, 2015 Glycosaminoglycan binding by *Borrelia burgdorferi* adhesin BBK32 specifically and uniquely promotes joint colonisation. *Cell Microbiol* 17, 860–875. [PubMed: 25486989]
- Liu T, Lu X, Zhao C, Fu X, Zhao T, Xu W, 2015 PD-1 deficiency enhances humoral immunity of malaria infection treatment vaccine. *Infect Immun* 83, 2011–2017. [PubMed: 25733520]
- Lobo CA, Cursino-Santos JR, Alhassan A, Rodrigues M, 2013 *Babesia*: an emerging infectious threat in transfusion medicine. *PLoS Pathog* 9, e1003387. [PubMed: 23853577]
- Luckett R, Rodriguez W, Katz D, 2014 Babesiosis in pregnancy. *Obstet Gynecol* 124, 419–422. [PubMed: 25004307]
- Lundqvist J, Larsson C, Nelson M, Andersson M, Bergstrom S, Persson C, 2010 Concomitant infection decreases the malaria burden but escalates relapsing fever borreliosis. *Infect Immun* 78, 1924–1930. [PubMed: 20145098]
- Magnarelli LA, Williams SC, Fikrig E, 2010 Seasonal prevalence of serum antibodies to whole cell and recombinant antigens of *Borrelia burgdorferi* and *Anaplasma phagocytophilum* in white-tailed deer in Connecticut. *J Wildl Dis* 46, 781–790. [PubMed: 20688684]
- Magnarelli LA, Williams SC, Norris SJ, Fikrig E, 2013 Serum antibodies to *Borrelia burgdorferi*, *Anaplasma phagocytophilum*, and *Babesia microti* in recaptured white-footed mice. *J Wildl Dis* 49, 294–302. [PubMed: 23568904]
- Marcus LC, Steere AC, Duray PH, Anderson AE, Mahoney EB, 1985 Fatal pancarditis in a patient with coexistent Lyme disease and babesiosis. Demonstration of spirochetes in the myocardium. *Ann Intern Med* 103, 374–376. [PubMed: 4040723]
- Marre ML, Petnicki-Ocwieja T, DeFrancesco AS, Darcy CT, Hu LT, 2010 Human integrin $\alpha(3)\beta(1)$ regulates TLR2 recognition of lipopeptides from endosomal compartments. *PLoS One* 5, e12871. [PubMed: 20877569]
- Martinez-Balzano C, Hess M, Malhotra A, Lenox R, 2015 Severe babesiosis and *Borrelia burgdorferi* co-infection. *QJM* 108, 141–143. [PubMed: 22685248]
- Matsubara J, Koura M, Kamiyama T, 1993 Infection of immunodeficient mice with a mouse-adapted substrain of the gray strain of *Babesia microti*. *J Parasitol* 79, 783–786. [PubMed: 8410556]
- Mayne PJ, 2011 Emerging incidence of Lyme borreliosis, babesiosis, bartonellosis, and granulocytic ehrlichiosis in Australia. *Int J Gen Med* 4, 845–852. [PubMed: 22267937]
- Mayne PJ, 2015 Clinical determinants of Lyme borreliosis, babesiosis, bartonellosis, anaplasmosis, and ehrlichiosis in an Australian cohort. *Int J Gen Med* 8, 15–26. [PubMed: 25565883]
- Menis M, Forshee RA, Kumar S, McKean S, Warnock R, Izurieta HS, Gondalia R, Johnson C, Mintz PD, Walderhaug MO, Worrall CM, Kelman JA, Anderson SA, 2015 Babesiosis Occurrence among the Elderly in the United States, as Recorded in Large Medicare Databases during 2006–2013. *PLoS One* 10, e0140332. [PubMed: 26469785]
- Miller JC, Maylor-Hagen H, Ma Y, Weis JH, Weis JJ, 2010 The Lyme disease spirochete *Borrelia burgdorferi* utilizes multiple ligands, including RNA, for interferon regulatory factor 3-dependent induction of type I interferon-responsive genes. *Infect Immun* 78, 3144–3153. [PubMed: 20404081]
- Mitchell PD, Reed KD, Hofkes JM, 1996 Immunoserologic evidence of coinfection with *Borrelia burgdorferi*, *Babesia microti*, and human granulocytic *Ehrlichia* species in residents of Wisconsin and Minnesota. *J Clin Microbiol* 34, 724–727. [PubMed: 8904446]
- Moore A, Nelson C, Molins C, Mead P, Schrieffer M, 2016 Current Guidelines, Common Clinical Pitfalls, and Future Directions for Laboratory Diagnosis of Lyme Disease, United States. *Emerg Infect Dis* 22.
- Moritz ED, Winton CS, Tonnetti L, Townsend RL, Berardi VP, Hewins ME, Weeks KE, Dodd RY, Stramer SL, 2016 Screening for *Babesia microti* in the U.S. Blood Supply. *N Engl J Med* 375, 2236–2245. [PubMed: 27959685]
- Moro MH, Zegarar-Moro OL, Bjornsson J, Hofmeister EK, Bruinsma E, Germer JJ, Persing DH, 2002 Increased arthritis severity in mice coinfecting with *Borrelia burgdorferi* and *Babesia microti*. *J Infect Dis* 186, 428–431. [PubMed: 12134242]

- Neelakanta G, Li X, Pal U, Liu X, Beck DS, DePonte K, Fish D, Kantor FS, Fikrig E, 2007 Outer surface protein B is critical for *Borrelia burgdorferi* adherence and survival within *Ixodes* ticks. PLoS Pathog 3, e33. [PubMed: 17352535]
- Obishakin E, de Trez C, Magez S, 2014 Chronic *Trypanosoma congolense* infections in mice cause a sustained disruption of the B-cell homeostasis in the bone marrow and spleen. Parasite Immunol 36, 187–198. [PubMed: 24451010]
- Oleson CV, Sivalingam JJ, O'Neill BJ, Staas WE, Jr., 2003 Transverse myelitis secondary to coexistent Lyme disease and babesiosis. J Spinal Cord Med 26, 168–171. [PubMed: 12828297]
- Oliver JH, Jr., Cummins GA, Joiner MS, 1993 Immature *Ixodes scapularis* (Acari: Ixodidae) parasitizing lizards from the southeastern U.S.A. J Parasitol 79, 684–689. [PubMed: 8410539]
- Ouhelli H, Schein E, 1988 Effect of temperature on transovarial transmission of *Babesia bigemina* (Smith and Kilborne, 1893) in *Boophilus annulatus* (Say, 1821). Vet Parasitol 26, 229–235. [PubMed: 3347984]
- Pal U, de Silva AM, Montgomery RR, Fish D, Anguita J, Anderson JF, Lobet Y, Fikrig E, 2000 Attachment of *Borrelia burgdorferi* within *Ixodes scapularis* mediated by outer surface protein A. J Clin Invest 106, 561–569. [PubMed: 10953031]
- Pal U, Li X, Wang T, Montgomery RR, Ramamoorthi N, Desilva AM, Bao F, Yang X, Pypaert M, Pradhan D, Kantor FS, Telford S, Anderson JF, Fikrig E, 2004 TROSPA, an *Ixodes scapularis* receptor for *Borrelia burgdorferi*. Cell 119, 457–468. [PubMed: 15537536]
- Parveen N, Cornell KA, Bono JL, Chamberland C, Rosa P, Leong JM, 2006 Bgp, a secreted GAG-binding protein of *B. burgdorferi* strain N40, displays nucleosidase activity and is not essential for infection of immunodeficient mice. Infect Immun 74, 3016–3020. [PubMed: 16622242]
- Parveen N, Leong JM, 2000 Identification of a candidate glycosaminoglycan-binding adhesin of the Lyme disease spirochete *Borrelia burgdorferi*. Mol Microbiol 35, 1220–1234. [PubMed: 10712702]
- Parveen N, Leong JM, 2006 Genetic analysis of attachment of *Borrelia burgdorferi* to host cells and extracellular matrix., in: Cabello FC, H. D, and Godfrey HP (Ed.), NATO Advanced Research Workshop on Lyme Disease IOS Press, Prague, Czech Republic, p. 400.
- Piesman J, Hicks TC, Sinsky RJ, Obiri G, 1987 Simultaneous transmission of *Borrelia burgdorferi* and *Babesia microti* by individual nymphal *Ixodes dammini* ticks. J Clin Microbiol 25, 2012–2013. [PubMed: 3667924]
- Poisnel E, Ebbo M, Berda-Haddad Y, Faucher B, Bernit E, Carcy B, Piarroux R, Harle JR, Schleinitz N, 2013 *Babesia microti*: an unusual travel-related disease. BMC Infect Dis 13, 99. [PubMed: 23432953]
- Primus S, Akoolo L, Schlachter S, Gedroic K, Rojzman AD, Parveen N, 2018 Efficient detection of symptomatic and asymptomatic patient samples for *Babesia microti* and *Borrelia burgdorferi* infection by multiplex qPCR. PLoS One 13, e0196748. [PubMed: 29746483]
- Pruthi RK, Marshall WF, Wiltse JC, Persing DH, 1995 Human babesiosis. Mayo Clin Proc 70, 853–862. [PubMed: 7643639]
- Radwanska M, Guirnalda P, De Trez C, Ryffel B, Black S, Magez S, 2008 Trypanosomiasis-induced B cell apoptosis results in loss of protective anti-parasite antibody responses and abolishment of vaccine-induced memory responses. PLoS Pathog 4, e1000078. [PubMed: 18516300]
- Raffalli J, Wormser GP, 2016 Persistence of babesiosis for >2 years in a patient on rituximab for rheumatoid arthritis. Diagn Microbiol Infect Dis 85, 231–232. [PubMed: 27036977]
- Rikihisa Y, 2010 *Anaplasma phagocytophilum* and *Ehrlichia chaffeensis*: subversive manipulators of host cells. Nature Rev Microbiol 8, 328–339. [PubMed: 20372158]
- Ristow LC, Bonde M, Lin YP, Sato H, Curtis M, Wesley E, Hahn BL, Fang J, Wilcox DA, Leong JM, Bergstrom S, Coburn J, 2015 Integrin binding by *Borrelia burgdorferi* P66 facilitates dissemination but is not required for infectivity. Cell Microbiol 17, 1021–1036. [PubMed: 25604835]
- Saetre K, Godhwani N, Maria M, Patel D, Wang G, Li KI, Wormser GP, Nolan SM, 2018 Congenital Babesiosis After Maternal Infection With *Borrelia burgdorferi* and *Babesia microti*. J Pediatric Infect Dis Soc 7, e1–e5. [PubMed: 28992325]
- Saidac DS, Marras SA, Parveen N, 2009 Detection and quantification of Lyme spirochetes using sensitive and specific molecular beacon probes. BMC Microbiol 9, 43–52. [PubMed: 19239692]

- Salazar JC, Duhnam-Ems S, La Vake C, Cruz AR, Moore MW, Caimano MJ, Velez-Climent L, Shupe J, Krueger W, Radolf JD, 2009 Activation of human monocytes by live *Borrelia burgdorferi* generates TLR2-dependent and -independent responses which include induction of IFN-beta. PLoS Pathog 5, e1000444. [PubMed: 19461888]
- Sasaki M, Fujii Y, Iwamoto M, Ikadai H, 2013 Effect of sex steroids on *Babesia microti* infection in mice. Am J Trop Med Hyg 88, 367–375. [PubMed: 23249689]
- Schlachter S, Seshu J, Lin T, Norris S, Parveen N, 2018 The *Borrelia burgdorferi* Glycosaminoglycan Binding Protein Bgp in the B31 Strain Is Not Essential for Infectivity despite Facilitating Adherence and Tissue Colonisation. Infect Immun 86.
- Seshu J, Esteve-Gassent MD, Labandeira-Rey M, Kim JH, Trzeciakowski JP, Hook M, Skare JT, 2006 Inactivation of the fibronectin-binding adhesin gene *bbk32* significantly attenuates the infectivity potential of *Borrelia burgdorferi*. Mol Microbiol 59, 1591–1601. [PubMed: 16468997]
- Shaio MF, Lin PR, 1998 A case study of cytokine profiles in acute human babesiosis. Am J Trop Med Hyg 58, 335–337. [PubMed: 9546414]
- Shi Y, Xu Q, Seemanapalli SV, McShan K, Liang FT, 2006 The dbpBA locus of *Borrelia burgdorferi* is not essential for infection of mice. Infect Immun 74, 6509–6512. [PubMed: 16954404]
- Sinski E, Welc-Faleciak R, Poglod R, 2011 *Babesia* spp. infections transmitted through blood transfusion. Wiad Parazytol 57, 77–81. [PubMed: 21682090]
- Skariah S, Arnaboldi P, Dattwyler RJ, Sultan AA, Gaylets C, Walwyn O, Mulhall H, Wu X, Dargham SR, Mordue DG, 2017 Elimination of *Babesia microti* Is Dependent on Intraerythrocytic Killing and CD4+ T Cells. J Immunol 199, 633–642. [PubMed: 28607116]
- Spielman A, Wilson ML, Levine JF, Piesman J, 1985 Ecology of *Ixodes dammini*-borne human babesiosis and Lyme disease. Annu Rev Entomol 30, 439–460. [PubMed: 3882050]
- Stafford KC, 3rd, Massung RF, Magnarelli LA, Ijdo JW, Anderson JF, 1999 Infection with agents of human granulocytic ehrlichiosis, lyme disease, and babesiosis in wild white-footed mice (*Peromyscus leucopus*) in Connecticut. J Clin Microbiol 37, 2887–2892. [PubMed: 10449470]
- Steere AC, 2001 Lyme disease. N Engl J Med 345, 115–125. [PubMed: 11450660]
- Steere AC, Drouin EE, Glickstein LJ, 2011 Relationship between immunity to *Borrelia burgdorferi* outer-surface protein A (OspA) and Lyme arthritis. Clin Infect Dis 52 Suppl 3, s259–265. [PubMed: 21217173]
- Strle K, Shin JJ, Glickstein LJ, Steere AC, 2012 Association of a Toll-like receptor 1 polymorphism with heightened Th1 inflammatory responses and antibiotic-refractory Lyme arthritis. Arthritis Rheum 64, 1497–1507. [PubMed: 22246581]
- Swanson SJ, Neitzel D, Reed KD, Belongia EA, 2006 Coinfections acquired from *Ixodes* ticks. Clin Microbiol Rev 19, 708–727. [PubMed: 17041141]
- Telford SR, 3rd, Dawson JE, Katavolos P, Warner CK, Kolbert CP, Persing DH, 1996 Perpetuation of the agent of human granulocytic ehrlichiosis in a deer tick-rodent cycle. Proc Nat Acad Sci USA 93, 6209–6214. [PubMed: 8650245]
- Thomas RJ, Dumler JS, Carlyon JA, 2009 Current management of human granulocytic anaplasmosis, human monocytic ehrlichiosis and *Ehrlichia ewingii* ehrlichiosis. Expert Rev Anti Infect Ther 7, 709–722. [PubMed: 19681699]
- Tilly K, Krum JG, Bestor A, Jewett MW, Grimm D, Bueschel D, Byram R, Dorward D, Vanraden MJ, Stewart P, Rosa P, 2006 *Borrelia burgdorferi* OspC protein required exclusively in a crucial early stage of mammalian infection. Infect Immun 74, 3554–3564. [PubMed: 16714588]
- van Vugt M, Wetsteyn JC, Haverkort M, Kolader M, Verhaar N, Spanjaard L, Grobusch MP, Bart A, van Gool T, 2011 New England souvenirs. J Travel Med 18, 425–426. [PubMed: 22017722]
- Vannier E, Borggraefe I, Telford SR, 3rd, Menon S, Brauns T, Spielman A, Gelfand JA, Wortis HH, 2004 Age-associated decline in resistance to *Babesia microti* is genetically determined. J Infect Dis 189, 1721–1728. [PubMed: 15116311]
- Wang TJ, Liang MH, Sangha O, Phillips CB, Lew RA, Wright EA, Berardi V, Fossel AH, Shadick NA, 2000 Coexposure to *Borrelia burgdorferi* and *Babesia microti* does not worsen the long-term outcome of lyme disease. Clin Infect Dis 31, 1149–1154. [PubMed: 11073744]

- Wang X, Ma Y, Yoder A, Crandall H, Zachary JF, Fujinami RS, Weis JH, Weis JJ, 2008 T cell infiltration is associated with increased Lyme arthritis in TLR2^{-/-} mice. *FEMS Immunol Med Microbiol* 52, 124–133. [PubMed: 18081848]
- Weening EH, Parveen N, Trzeciakowski JP, Leong JM, Hook M, Skare JT . , 2008 *Borrelia burgdorferi* lacking DbpBA exhibit an early survival defect during experimental infection. *Infect Immun* 76, 5694–5705. [PubMed: 18809667]
- Western KA, Benson GD, Gleason NN, Healy GR, Schultz MG, 1970 Babesiosis in a Massachusetts resident. *N Engl J Med* 283, 854–856. [PubMed: 4989787]
- Wooten RM, Ma Y, Yoder RA, Brown JP, Weis JH, Zachary JF, Kirschning CJ, Weis JJ, 2002 Toll-like receptor 2 plays a pivotal role in host defense and inflammatory response to *Borrelia burgdorferi*. *Vector Borne Zoonotic Dis* 2, 275–278. [PubMed: 12804169]
- Wormser GP, Villafuerte P, Nolan SM, Wang G, Lerner RG, Saetre KL, Maria MH, Branda JA, 2015 Neutropenia in Congenital and Adult Babesiosis. *Am J Clin Pathol* 144, 94–96. [PubMed: 26071466]
- Yoder A, Wang X, Ma Y, Philipp MT, Heilbrun M, Weis JH, Kirschning CJ, Wooten RM, Weis JJ, 2003 Tripalmitoyl-S-glycerol-cysteine-dependent OspA vaccination of toll-like receptor 2-deficient mice results in effective protection from *Borrelia burgdorferi* challenge. *Infect Immun* 71, 3894–3900. [PubMed: 12819074]

Highlights

- Incidence of babesiosis and Lyme disease is high in the U.S.A. and Europe
- Coinfection by *Babesia microti* and *Borrelia burgdorferi* shows diverse and persistent symptoms in patients
- *Babesia microti* infection reduces hemoglobin and hematocrit levels, and results in anemia
- The spleen, as a lymphoid organ, plays an important role in clearance of *B. microti* during infection
- Coinfection with *B. burgdorferi* and *B. microti* attenuates parasite growth while exacerbating Lyme disease symptoms in mice




Fig. 1.

Babesia microti peak parasitaemia was followed by a pronounced decrease in haemoglobin levels. (A) Giemsa-stained blood smears reveal intra-erythrocytic pleomorphic forms at peak parasitaemia in *B. microti*-infected mice (40 × magnification). (B and C) Asterisk indicates that *B. microti*-*Borrelia burgdorferi* coinfecting mice (B) display significantly lower peak parasitaemia (marked by triangles) compared with mice infected with *B. microti* alone (C). Furthermore, increase in *B. microti* parasitaemia was accompanied with sharp declines in haemoglobin levels (circles). Haemoglobin returned to normal levels after resolution of parasitaemia. Significance was determined by a student's *t* test for unequal variance (*statistically significant difference in parasitaemia, $P < 0.05$).




Fig. 2.

Babesia microti stimulates changes in splenic architecture irrespective of the presence of *Borrelia burgdorferi*. (A) Spleens in *B. burgdorferi*-infected C3H/HeJ mice have well-demarcated red pulp, marginal zone and white pulp regions. (B) Spleens of coinfecting mice display enlargement and merging of red pulp, marginal zone and white pulp regions.